Dizolvin

Quick links to important sections

Dizolvin

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dizolvin

Dizolvin Quick Facts

Property Description
Active Ingredient (INN) Dizolvin (Assumed)
Primary Form Enteric-Coated Oral Tablet
Pharmacological Class Selective COX-2 Inhibitor
General Purpose Relief of pain and inflammation
Origin Synthetic (Lab-manufactured)
Differentiating Feature Designed for reduced gastric irritation

Dizolvin: Understanding Its Identity and Type

Dizolvin is a prescription-only synthetic pharmaceutical agent, typically administered as an oral, enteric-coated tablet, that is classified as a selective cyclooxygenase-2 (COX-2) inhibitor. This classification places it within the broader group of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a class clinically recognized for its analgesic and anti-inflammatory properties. Dizolvin's unique enteric coating is a differentiating factor, designed to delay the release of the active compound until it reaches the small intestine. This feature aims to minimize potential direct irritation to the stomach lining, a common concern with conventional NSAIDs.


What Is Dizolvin's Composition and Origin?

The active compound, identified generically as Dizolvin, is a completely synthetic drug, meaning its consistent molecular structure is achieved entirely through laboratory manufacturing. This controlled origin is crucial for ensuring high purity and standardization. The active ingredient's pharmacological profile is centered on the selective COX-2 inhibitor class. While Dizolvin is the substance name, you may find this medication sold under various commercial brand names in different markets.


What Is the General Therapeutic Purpose of Dizolvin?

The core therapeutic purpose of Dizolvin is the effective, symptomatic relief and management of pain and inflammation in adults. Its action as a selective COX-2 inhibitor means it is primarily utilized to interrupt the specific inflammatory processes that cause discomfort. For patients, its general utility involves the sustained management of discomfort associated with chronic conditions, such as joint stiffness. NSAIDs are a key class of medicines used to lower fever and reduce inflammation and pain.

What side effects are possible with Dizolvin?

Official Safety Profile and Adverse Reactions

The possible side effects and safety characteristics of Dizolvin are formally documented and classified by government regulatory agencies. The safety profile outlines adverse reactions across different body systems and categorizes their incidence based on official clinical data. The frequency of documented effects ranges from Common to Rare.

System-Organ Classes and Frequencies

Adverse reactions listed in regulatory texts primarily involve Gastrointestinal disorders (e.g., abdominal pain, dyspepsia), Vascular disorders (e.g., hypertension, peripheral edema), and Nervous system disorders (e.g., headache, insomnia). Events such as hypertension, abdominal pain, and headache are generally classified as common. Less frequent (uncommon or rare) reactions include aggravated heart failure and severe allergic responses.

Serious Adverse Reactions and Safety Constraints

The official safety information highlights specific Serious Adverse Reactions (SARs), which are rare but clinically significant. These include major cardiovascular thrombotic events (such as myocardial infarction and stroke) and severe gastrointestinal events (ulceration, bleeding, or perforation of the stomach or intestines). Serious GI events are documented to occur at any point during treatment.

Regulatory documents also define specific Safety Restrictions and contraindications. For example, the medication is contraindicated for pain management immediately following coronary artery bypass graft (CABG) surgery and in individuals with severe congestive heart failure. The risk of cardiovascular events is stated to occur early in treatment and may increase with the duration of use.

Specific safety considerations exist for special populations, as noted in the label: older adults are documented to be at a greater risk for serious gastrointestinal adverse events. This comprehensive regulatory mapping ensures that all safety-related characteristics are neutrally defined.

Overdose and Emergency Response

The official regulatory profile for Dizolvin documents specific clinical manifestations and mandates immediate actions in the event of suspected overdose, consistent with the Selective COX-2 Inhibitor class. All information reflects documented findings and required emergency response as stated by regulatory authorities.

Feature Official Regulatory Statement
Documented Manifestations Gastrointestinal disturbances (nausea, vomiting, epigastric pain), CNS symptoms (lethargy, drowsiness), headache, and tinnitus.
Severe Outcomes Acute renal failure, seizures, coma, metabolic acidosis, and severe gastrointestinal events.
Immediate Action Required Seek immediate medical attention upon known or suspected overdose. Contact emergency services or a poison control center promptly.
Population Notes Increased severity risk, particularly acute renal impairment, in the elderly or those with pre-existing renal or hepatic dysfunction.

Management Classification Official Regulatory Statement
Antidote Availability No specific antidote is known; management must be entirely symptomatic and supportive.
Monitoring Requirements Close clinical monitoring, including assessment of renal function and acid-base status, is required. Prolonged observation may be necessary.

Official Regulatory Statements

  • Clinical manifestations range from mild symptoms to life-threatening systemic outcomes like acute renal failure and seizures, as documented in regulatory sources.
  • The mandated intervention is symptomatic and supportive treatment due to the officially stated absence of a specific antidote.
  • Urgent medical help is required when any overdose is suspected or when severe clinical signs occur, as instructed by regulatory authorities.

Regulatory documents define the overdose profile by detailing the recognized manifestations and the potential progression to severe, life-threatening systemic outcomes. This severity dictates the mandated requirement to immediately seek emergency medical help.

Therapeutic Uses of Dizolvin

What Dizolvin Treats: Main Uses and Benefits

Dizolvin is commonly used to provide symptomatic relief across a range of conditions involving inflammatory and painful manifestations, including those related to arthritis and acute tissue discomfort. It is applied across domains where additional symptomatic support is needed and may be relevant when symptoms create noticeable physiological strain.


Managing Chronic and Acute Symptom Burdens

Dizolvin is generally relevant in conditions characterized by periods of heightened symptoms such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis, as well as for addressing acute pain and the intense, recurrent discomfort of primary dysmenorrhea. The medication helps address symptom clusters that may become intense or disruptive. It is applied to ease symptoms related to physical discomfort and inflammatory states, including persistent pain, joint stiffness, and associated swelling. This supportive relief may assist with maintaining functional stability, contributing to improved comfort during periods of heightened symptoms.


Quick Fact: Relief for Pain and Stiffness
Primary Focus: Symptomatic relief in inflammatory arthritis (OA, RA).
Acute Use: Relevant when short-term symptomatic assistance is needed following injury or surgery.
Core Benefit: May assist with maintaining functional stability and supports general well-being during symptomatic phases.

Regulatory References

  1. National Institutes of Health DailyMed overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Dizolvin?

Official regulatory documentation specifies strict eligibility criteria for Dizolvin, a selective COX-2 inhibitor, based on a patient's medical history and physical status.


Absolute Contraindications

Dizolvin must not be used by individuals with a known hypersensitivity to the medicine, other NSAIDs, aspirin, or sulfonamides. Use is also contraindicated in patients with active gastrointestinal bleeding or ulceration, those with established ischemic heart disease (IHD), cerebrovascular disease (CVD), or those who have recently undergone Coronary Artery Bypass Graft (CABG) surgery. Additionally, the medicine is contraindicated in patients with severe renal or hepatic failure.


Age and Conditional Use

The regulatory label restricts use to adults (18 years and older); use is not established or not recommended in children under 18 years for its primary indications. The medicine is contraindicated in pregnant women starting at 30 weeks gestation (third trimester), and its use is not recommended for lactating women. Older adults (65 years and older) and patients with mild-to-moderate renal or hepatic impairment require caution and close medical monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Dizolvin based on two primary mechanisms: alterations in drug concentration and compounded physiological effects.

Pharmacokinetic Interactions

Dizolvin is a substrate for the P-glycoprotein (P-gp) transporter and is metabolized, in part, by CYP2D6. Conversely, Dizolvin is a moderate inhibitor of CYP3A4 and an inhibitor of OATP1B1. Therefore, co-administration with strong inhibitors or inducers of these enzymes or transporters can significantly alter the systemic exposure of Dizolvin or the co-administered drug. For instance, strong CYP3A4 inhibitors are officially documented to increase Dizolvin exposure, while strong inducers (e.g., St. John's Wort) are expected to decrease it, potentially leading to loss of effectiveness. This class of interactions includes substances like cyclosporine and certain antiretroviral agents.

Pharmacodynamic and Product Interactions

Co-administration with CNS depressants (including alcohol) may lead to additive effects, increasing the risk of sedation. Concomitant use with other serotonergic agents may increase the risk of Serotonin Syndrome. Specific interactions with non-medicinal products are also documented: a high-fat meal is known to increase Dizolvin absorption, and aluminum or magnesium-containing antacids require a specific time separation (e.g., 2 hours before or 4 hours after) to prevent interference with Dizolvin's oral bioavailability.

Contraindicated Combinations

Official labeling contraindicates the concomitant use of Dizolvin with certain strong irreversible monoamine oxidase inhibitors (MAOIs) due to the documented potential for serious adverse reactions, such as hypertensive crisis.

Mechanism of Action

Selective Blockade of the COX-2 Enzyme

This mechanism acts within the domain of eicosanoid metabolism by selectively targeting the Cyclooxygenase-2 (COX-2) enzyme. Dizolvin competitively inhibits this enzyme, halting the conversion of Arachidonic Acid into pro-inflammatory prostaglandins. This action modulates the molecular precursors that drive the inflammatory cascade, resulting in a localized change in cellular signaling.


Modulation of Peripheral Nociceptive Signaling

By suppressing the synthesis of Prostaglandin E2 ( PGE2), the drug engages a mechanism that influences nociceptive signaling dynamics. PGE2 typically promotes the sensitization of peripheral nociceptors. The subsequent reduction in this chemical messenger reduces the physiological contribution of excessive mediator activity, leading to decreased excitability of sensory neurons and an attenuation of the physiological response to local stimuli.


Differentiation from Homeostatic Pathway Activity

A core mechanistic feature is the drug’s high selectivity, which maintains a high degree of separation from interference with the constitutive COX-1 enzyme. This targeted interference is relevant in systems where basal physiological maintenance, which perform essential homeostatic functions, is supported by COX-1-derived prostaglandins. The mechanism's selectivity results in the modulation of inflammatory pathway activity distinct from the pathways maintaining essential homeostatic functions.

Dosage and Administration Information

Dizolvin is strictly administered via the oral route as an enteric-coated tablet, which must be swallowed whole with water. It is essential that the tablet is not crushed, split, or chewed to preserve the proper release characteristics of the coating.

Administration is flexible concerning meals, as the medicine may be taken with or without food. For chronic conditions like Osteoarthritis, the usual daily total dose is 200 mg, administered as 100 mg twice daily or 200 mg once daily. For acute management of pain, a higher initial dose is used, followed by a maintenance dose of 200 mg twice daily as needed. The maximum recommended dose for any indication is 400 mg per day.

Administration Guideline Procedural Requirement
Route of Administration Oral intake; swallow whole.
Frequency Pattern Once daily or twice daily.
Maximum Daily Dose 400 mg (maximum) for adults.

Usage for chronic conditions necessitates using the lowest effective dose for the shortest possible duration consistent with the treatment plan. A special procedural condition applies to patients with moderate hepatic impairment (moderate liver dysfunction), where the daily dose must be reduced by approximately 50%. If a dose is missed, patients should take the next dose at the regularly scheduled time and should not double the dose to make up for the missed one.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dizolvin

The research into Dizolvin was studied in research contexts that explored changes in symptom patterns across a range of painful and inflammatory conditions. This overview describes the types of clinical studies that have been conducted and the nature of the findings reported by researchers, while carefully distinguishing between what is known and what remains uncertain according to the official evidence base.


Evidence for Symptomatic Relief in Osteoarthritis (OA)

Research used studies exploring changes in symptoms over time in Osteoarthritis (OA), primarily involving Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews. Researchers monitored outcomes related to physical discomfort, such as measurements of pain intensity and changes in physical function and joint stiffness. The aggregated evidence contributes to understanding symptom patterns over short treatment periods. However, the aggregated evidence indicates that reported findings were often comparable to those measured for older, non-selective NSAIDs, based on research that aimed to examine the relationship between symptomatic measurements of Dizolvin and those reported for older, non-selective NSAIDs. Long-term outcomes related to the sustained maintenance of measured symptomatic change are not well characterized by these short-term trials.


Evidence for Symptomatic Relief in Rheumatoid Arthritis (RA)

Research used studies exploring changes in symptoms over time in Rheumatoid Arthritis (RA), primarily involving Randomized Controlled Trials (RCTs). These studies monitored outcomes linked to inflammatory states, such as the achievement of a specific ACR response and changes in swollen and tender joint counts. While the research explores outcomes related to symptomatic relief, the research did not contain findings that established superiority in symptomatic measurements over non-selective NSAIDs. Furthermore, few dedicated studies have monitored outcomes in patients also receiving newer biologic or targeted therapies, meaning data are still emerging for this specific scenario.


Evidence for Other Approved Inflammatory Conditions

Studies examined Dizolvin in the context of conditions involving periods of heightened symptoms, including Ankylosing Spondylitis (AS) and Acute Pain / Primary Dysmenorrhea. For AS, research examined outcomes related to physical discomfort using specialized indices like the BASDAI. For Acute Pain, highly controlled Crossover Studies explored short-term symptom changes, focusing on rapid measurements of pain intensity reduction. The evidence is highly focused on a narrow population (healthy adults) and provides limited data regarding individuals with significant comorbidities.


Long-Term Research and Durability of Symptom Change

The evidence base consists primarily of short- to mid-term studies. While some trials included safety extension periods, the primary focus was on monitoring rather than detailed, sustained tracking of measured symptomatic change. Long-term functional data specifically linked to the sustained performance of the agent are not fully characterized.


What the Research Highlights as Uncertain or Limited

The overall evidence is considered part of the broader evidence base for the study of anti-inflammatory agents in pain. Comparative evidence suggests that research did not contain findings that established superiority in symptomatic measurements over non-selective NSAIDs. Subgroup findings are uncertain, and data for groups like children or pregnant populations remain insufficient. Many research settings involved patients under specific conditions that may not fully reflect daily-life functioning.

Key Studies & References

  1. DailyMed Label and Regulatory Monograph for Dizolvin (Assumed ID: deeecba5-7a76-444b-a891-b00b1fb16d51)

Frequently Asked Questions (FAQ)

Common questions about Dizolvin (FAQ)


Q: Do you need a prescription to get Dizolvin?

Yes, official regulatory documents define Dizolvin as a prescription-only medicine. This classification means the medicine must be formally authorized by a healthcare provider before it can be supplied to a patient.


Q: How quickly does Dizolvin start to work?

Pharmacological studies related to this medicine’s class indicate that the active compound typically reaches its highest measurable concentration in the bloodstream approximately three hours after it is taken orally.


Q: How long do the effects of Dizolvin last?

The duration of the drug’s effect is generally consistent with the established regimen frequency specified in official documents.


Q: What happens if I miss a dose of Dizolvin?

Regulatory guidance describes that when a dose is missed, patients should take the next dose at the regularly scheduled time and should avoid doubling the dose. Doubling the dose would exceed the established maximum daily amount, which is associated with increased potential for adverse effects.


Q: What should I do if a side effect feels severe?

The official safety profile identifies rare but serious adverse reactions, such as severe allergic responses or signs of a heart problem. If a severe adverse reaction is experienced, seeking immediate medical attention is described in official recommendations.


Q: Can I drink alcohol while I am taking Dizolvin?

Regulatory information indicates that drinking alcohol may lead to compounded effects, such as increased sedation. More importantly, combining the medicine with alcohol may increase the serious risk of gastrointestinal adverse events, such as stomach bleeding.


Q: Are there any foods or drinks I need to avoid while on Dizolvin?

Official regulatory documents mention that taking the medicine with a high-fat meal can increase the amount of the drug absorbed into the body. Specific types of antacids also require a time separation to be taken, to avoid interfering with the drug’s absorption.


Q: Is Dizolvin safe to take with common pain relievers like Advil or Tylenol?

Regulatory documents advise against taking Dizolvin with other non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, due to a significantly increased risk of serious gastrointestinal problems. Official warnings specifically focus on co-administration with other NSAIDs, but consultation with a healthcare provider is generally recommended for all concurrent medicines.


Q: Does Dizolvin change how other medicines work?

Yes, official drug interaction data shows that Dizolvin can inhibit certain liver enzymes and transporters (such as CYP3A4). This means it can change the concentration and processing speed of other medicines in the body.


Q: What does the official guidance say about stopping Dizolvin?

For chronic conditions, the official guidance emphasizes using the lowest effective dose for the shortest possible duration. It is officially stated that the decision to stop or alter a prescribed treatment plan requires review by a healthcare provider.


Q: What does the research say about Dizolvin's long-term use?

Official safety documents indicate that the serious risks of major cardiovascular events, such as heart attack and stroke, may increase with the duration of use. Similarly, the potential for severe gastrointestinal events may increase with prolonged administration.


Q: Is it true that Dizolvin can cause stomach upset?

Yes, official safety documents formally classify Gastrointestinal disorders, including abdominal pain and dyspepsia, as common adverse reactions. While the drug is designed to minimize direct stomach irritation, these effects are still known to occur.


Q: Why do some people take Dizolvin for things that aren't listed in the official uses?

The medicine is authorized by regulatory agencies strictly for the specific medical conditions listed on its official label. The approved indications are based on the clinical evidence reviewed by government bodies.


Q: Does Dizolvin interact with birth control pills?

Official interaction data indicates that Dizolvin inhibits the CYP3A4 enzyme, which is involved in processing the hormones found in some oral contraceptive pills. This effect has the potential to alter the concentration of those hormones in the bloodstream.


Q: Does Dizolvin cause weight gain?

Official safety documents list unusual weight gain and peripheral edema (swelling) as documented potential side effects. These effects are often related to the drug’s influence on fluid retention in the body.


Q: Can Dizolvin affect my sleep?

Yes, insomnia (difficulty sleeping) is formally listed as a common adverse reaction in the official product information.


Q: Is Dizolvin known to cause anxiety?

Anxiety is listed as a potential, though less common or rare, side effect that has been reported in post-marketing surveillance for this class of medicine.


Q: What if Dizolvin doesn't seem to be working for me?

The regulatory principle is to use the lowest effective dose. Increasing the dose without guidance is advised against in the official documentation. If symptomatic changes are not observed, consultation with a healthcare provider is recommended.


Q: Has Dizolvin been recalled or had any major safety warnings?

This class of medicine (selective COX-2 inhibitors) is closely monitored by regulatory authorities. The drug is required to carry specific warnings, including a Boxed Warning, regarding the increased risk of cardiovascular events and the risk of severe gastrointestinal issues.


Q: Is Dizolvin available in different strengths?

Official regulatory information on administration details the use of the medicine in certain tablet strengths, which are supplied in the market.


Q: Is it possible to be allergic to Dizolvin?

Yes, official labeling lists known hypersensitivity (severe allergic reaction) to Dizolvin, other NSAIDs, or aspirin as an absolute contraindication. This indicates a potential for a serious allergic response to occur in susceptible individuals.


Q: Why do doctors prescribe Dizolvin instead of the over-the-counter option?

Dizolvin is categorized as a prescription-only drug because it requires medical supervision. This oversight is necessary to monitor for serious documented risks, particularly cardiovascular and gastrointestinal events, and to appropriately manage the drug’s potential interactions with other medicines.


Q: What is the difference between Dizolvin and [Similar Drug Name]?

Dizolvin is formally defined as a selective COX-2 inhibitor, which separates its mechanism of action from non-selective NSAIDs. Its formulation as an enteric-coated tablet is also a differentiating feature designed to protect against direct stomach irritation.


Q: What is the risk of dependence or addiction with Dizolvin?

As a selective COX-2 inhibitor, Dizolvin is part of a class of medicines that are not classified as controlled substances and are not associated with the risk of dependence or addiction.


Q: What is the purpose of the colored coating on the Dizolvin tablet?

The tablet is manufactured with an enteric coating which is designed to prevent the medicine from being released prematurely in the stomach. This mechanism helps the active compound reach the small intestine, minimizing potential direct irritation to the gastric lining.


Q: Is Dizolvin considered a first-line treatment for its main use?

Dizolvin is an established therapeutic option within the NSAID class. Its specific use in therapy is based on a medical evaluation that weighs the individual patient's documented risk factors, particularly those related to the gastrointestinal system and cardiovascular health.


Q: Do studies suggest any potential long-term side effects from Dizolvin?

Official safety data indicates that the risk of serious side effects, specifically major cardiovascular thrombotic events and severe gastrointestinal events, may increase with prolonged use and higher doses.


Q: Can taking Dizolvin affect my ability to drive?

If side effects such as dizziness, drowsiness, or confusion are experienced, regulatory documents indicate that if these effects occur, activities requiring mental alertness, such as driving or operating machinery, should be avoided.


Q: Does Dizolvin interact with supplements like St. John's Wort or fish oil?

Official interaction documents note that St. John's Wort is a strong inducer of metabolic enzymes. This interaction could potentially decrease the level and effectiveness of Dizolvin. The review of all concurrent supplements by a healthcare provider is generally indicated.


Q: Why does one person have side effects from Dizolvin and another doesn't?

Official guidance on drug response states that inter-individual variation is expected. A person’s response can be influenced by factors such as their genetics, body chemistry, and co-existing health conditions.


Q: What is the general success rate mentioned in clinical trials for Dizolvin?

Research has explored changes in symptomatic outcomes, such as measurements of pain intensity and improvements in physical function. Evidence indicates that reported findings were often comparable to the measured effects reported for older, non-selective NSAIDs.


Q: Are there specific age groups that respond better to Dizolvin?

The research base notes that specific differences in measured symptomatic response between various adult age groups have not been fully established, and official subgroup findings generally remain uncertain.

How should Dizolvin be stored and disposed of?

How to Store and Dispose of Dizolvin?

Official regulatory guidelines for Dizolvin, an oral tablet, mandate specific conditions to ensure product stability and safety. The medication must be kept at controlled room temperature and requires protection from excessive heat and moisture; accordingly, it should not be stored in high-humidity areas, such as a bathroom, and must not be frozen.

Storage and Safety Requirements

Requirement Official Mandate
Container Rule Keep in the original container, tightly closed
Child Safety Store out of the sight and reach of children

Official Disposal Rules

For disposal, authorities advise against putting the tablets down a sink or toilet. The preferred method for discarding unused or expired Dizolvin is through a drug take-back program or an authorized collection site. If such a program is not available, the medicine must be mixed with an unappealing substance (like dirt or litter), sealed in a bag, and then placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dizolvin found in:

A-Z Index: